|
|
|
|
|
|
11.10: In Vivo
Continuous Glucose Monitoring: A Case Study for Commercializing Products in the Era of Patient-Driven Health Care
Contributing Authors:
Marie Schiller, Partner, Sheela Hegde, Vice President, and Brittany Carroll, Associate
While continuous glucose monitoring offers significant value to a broad range of patients, the technology has
still not fulfilled its market potential. Many hurdles to adoption still exist including product accuracy issues,
ease-of-use hurdles, and insufficient payer coverage. However, for patients who have successfully built CGM into
their therapeutic plan, the results have been impressive. So why is a technology that can have such a meaningful
impact on some individuals gaining traction so slowly?
Continuous glucose monitoring presents an example of how an individual product has far less value than the integrated
solution the technology enables. The greatest obstacle in CGM is the disconnect between CGM and treatment planning;
CGM produces mounds of data that patients and even physicians don't know how to use. If this powerful dataset could
be optimized, shared, and applied, it could shift CGM from a niche product for a small number of type 1 diabetes
patients into a standard of care for many metabolic diseases.
Such a shift, however, will require changes in the mindset of product companies. Traditional commercialization strategies
involve driving discrete products and maximizing product value through lifecycle enhancements. In a new patient-driven system,
alternative strategies to develop a broader solution to treatment planning will capture new sources of value.
 request a reprint.
learn more about Health Advances' expertise in diabetes.
12.08: Start-Up Magazine
Will Simpler Devices Tap the Largest Diabetes Market?
By Marie Schiller, Andrew Funderburk, Sheela Hegde, and Kathryn Strayer-Benton
Historically, technological advances to the insulin pump market have concentrated on slow but
steady improvements to the pump's functionality, size and design. What the market hasn't yet
experienced are dramatic improvements that would embrace the needs of both type 1 and type 2
diabetes patients while keeping costs low. This may be changing as companies expand their focus
on developing simpler, lower cost insulin pumps that will benefit a broad spectrum of diabetes
patients and providers. Health Advances Diabetes Practice Group shares its thoughts on the push
to move insulin pump therapy into the larger type 2 diabetes population and some of the hurdles
that will need to be overcome.
request a reprint
return to Health Advances' diabetes focus area.
Beta Cell Regeneration: A Look into the Future of Diabetes Management
The existing arsenal of diabetes treatments has significantly reduced the unmet need for
incremental improvements in glucose management. Next generation products will need to
offer "glucose plus" or be disease-modifying agents. This dynamic is driving heightened
interest in beta cell regeneration, the next potential breakthrough in diabetes treatment.
Several diabetes market leaders - including Lilly, Novo Nordisk and Takeda - have already
made related investments in early stage companies.
Beta cell regeneration's potential to be competitive or synergistic with other treatments
brings up questions on its place in the type 1 and type 2 diabetes treatment paradigms.
Health Advances interviewed JDRF's Executive VP, Research - Richard Insel MD, Lilly's
Executive Director, Global Diabetes Brands - Thane Wettig, and Transgeneron Therapeutics'
CEO - Leslie Molony PhD, to discuss the potential therapeutic positioning of beta cell
regeneration therapies in type 1 and type 2 diabetes. The following is an excerpt from the
virtual roundtable:
Health Advances: Where should a beta cell regeneration therapy be positioned in type 2
diabetes treatment?
Thane Wettig: "I think what is coming into vogue nowadays, more so than in the past,
is this idea that the better you do early on with controlling glucose, the better the
long-term prognosis for the patient. And so, if we treat someone very aggressively upon
diagnosis of type 2 diabetes and get them under good control for a prolonged period of time,
there is a lot of upside for that patient in the long-term. I think there are a lot of people
who just have thrown their arms up in the air, and said, 'well, metformin will always
be used first.' We don't necessarily think that's the case."
Leslie Molony: "Well, theoretically the entire population could benefit . . . But
the catch is what patient population will be approved. Obviously regeneration is a new
treatment paradigm. Our plan is to look at the end stage type 2 patients initially and see if we can reduce the need for insulin
or eliminate the need for insulin."
request a copy
return to Health Advances' diabetes focus area.
Proprietary Diabetes Forecasting Tool
For the past 17 years, Health Advances has analyzed the diabetes market and developed sophisticated product forecasts for its clients. Our work has consistently demonstrated that developing accurate product forecasts in diabetes is more complicated than in other therapeutic areas. Specific factors that make this process more challenging include:
- Prevalence is growing due to increases in both incidence rates and survival rates
- Age at diagnosis and rate of disease progression are highly variable
- Mortality is not directly linked to stage of disease
- Treatment paradigms are shifting
- Penetration varies by specialty
request more information.
return to Health Advances' diabetes focus area.
|
|
 |
|
|
|
|
